Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

101. Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder

Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0349. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that guanfacine hydrochloride extended release (GXR) not be listed. Final

2014 Health Technology Assessment (HTA) Database.

102. Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders

not associated with subsequent substance use disorders Paula D Riggs Statistics from Altmetric.com Commentary on: Humphreys KL , Eng T , Lee SS , et al . Stimulant medication and substance use outcomes: a meta-analysis . Context Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood, affecting 3–7% of school-age children. 1 Stimulant medication is an effective treatment for childhood ADHD and is well established as a first-line treatment in most clinical (...) Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2014 Evidence-Based Medicine

103. Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD)

Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - lisdexamfetamine dimesylate (Elvanse) | | Appraisal information Search and reports lisdexamfetamine dimesylate (Elvanse®) Reference No. 188 Publication date: 03/12/2013 Last review date: 01/12/2016 Appraisal information lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule lisdexamfetamine dimesylate (Elvanse® (...) programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders. Final Appraisal Recommendation (FAR) Download AWMSG Secretariat Appraisal Report (ASAR) Download Clinical Expert (CE) Summary Download |

2013 All Wales Medicines Strategy Group

104. Clinical practice: Adult attention deficit-hyperactivity disorder. Full Text available with Trip Pro

Clinical practice: Adult attention deficit-hyperactivity disorder. Short-term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long-term benefits and risks of these medications, particularly among older persons, have been insufficient.

2013 NEJM

105. Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence

age 43) (cross-over study) Randomized, double- blind, placebo- controlled, cross-over study 6 weeks Improvement in ADHD symptoms measured by the DSM-IV ADHD Behavior Checklist for Adults, the Controlled Oral Word Association Test (COWAT), Stroop and Digit Span Safety (adverse effects) ADHD: attention-deficit/hyperactivity disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4 th edition) Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for ADHD 12 Appendix 3 (...) by the owners’ own terms and conditions. TITLE: Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence DATE: 21 March 2013 CONTEXT AND POLICY ISSUES Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with inappropriate levels of inattention, hyperactivity, and impulsivity manifesting in childhood and continuing into adulthood, resulting in functional

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

106. Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review (Abstract)

Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review The US Agency for Healthcare Research and Quality sponsored a comparative effectiveness review of interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD).Medline, Cochrane CENTRAL, Embase, PsycInfo, and Education Resources Information Center were searched from 1980 to November 24, 2011. Selected studies were comparative, and enrolled children <6 years with clinically (...) significant disruptive behavior, including ADHD. The interventions evaluated were parent behavior training (PBT), combined home and school/day care interventions, and methylphenidate use. Data were extracted by using customized software. Two independent raters evaluated studies as good, fair, or poor by using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies Risk of Bias. Overall strength of evidence (SOE) was rated for each intervention's effectiveness

2013 EvidenceUpdates

107. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine dimesylate is a pharmacologically inactive pro-drug that is converted into the central nervous system stimulant, dexamfetamine. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guideline CG72, published in 2008) recommends that drug treatment for children and young people (...) with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice/interventions. It also recommends Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20that when drug treatment of ADHD is considered appropriate, methylphenidate, atomoxetine

2013 National Institute for Health and Clinical Excellence - Advice

108. Attention deficit hyperactivity disorder in children and young people: clonidine

Behavior Disorders"/ (20051) 22 (hyperactiv* or adhd or "attention deficit").ab,ti. (36749) 23 21 or 22 (42937) Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 26 of 2924 Clonidine/ (12346) 25 (clonidine or clon-ir or clon-xr or catapres).tw. (13055) 26 24 or 25 (16313) 27 23 and 26 (449) 28 14 and 27 (15) 29 19 and 27 (69) 30 28 (...) ), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Clonidine is an alpha 2 -adrenergic agonist that is licensed in the UK for adults to prevent migraine, prevent hot flushing associated with menopause, and treat hypertension. It does not have a UK licence to treat attention deficit hyperactivity disorder (ADHD) in any age group. It is sometimes used off-label (generally as an add-on to a licensed psychostimulant medicine, such as methylphenidate) to treat ADHD

2013 National Institute for Health and Clinical Excellence - Advice

109. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin

, Starreveld JS et al. (2003) Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. European Journal of Pediatrics 162: 554–5 van der Heijden KB, Smits MG, Someren EJ et al. (2007) Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. Journal of the American Academy of Child and Adolescent Psychiatry 46: 233–41 Waldron D, Bramble D, Gringas P (2005) Melatonin: prescribing practices (...) , characterised by poor quality of sleep, in adults who are aged 55 years or over. Additional melatonin products are available from special-order manufacturers or specialist importing companies, or can be purchased directly online. No high-quality studies were identified that provided evidence for the efficacy of prolonged- release melatonin tablets (licensed in the UK) used off-label in children with sleep disorders and attention deficit hyperactivity disorder (ADHD). Limited evidence for unlicensed

2013 National Institute for Health and Clinical Excellence - Advice

110. Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder 1 Quality Department Guidelines for Clinical Care Ambulatory ADHD Guideline Team Team Leaders John M O'Brien, MD Family Medicine Jennifer G. Christner, MD Child Behavioral Health Team Members Bernard Biermann, MD, PhD Child/Adolescent Psychiatry Barbara T Felt, MD Child Behavioral Health R Van Harrison, PhD Medical Education Paramjeet K Kochhar, MD General Pediatrics Consultant Darcie-Ann Streetman, PharmD College of Pharmacy Initial Release August, 2005 (...) of child’s self-identified impression of function, both strengths and weaknesses • Clinician’s observations of child’s behavior • Physical and neurologic examination Note: From ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, American Academy of Pediatrics, Nov. 2011 Table 4. Treatment Options for ADHD For pre-school aged children, first line is behavior therapy. If not significantly improved, prescribe

2013 University of Michigan Health System

111. [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]

disorder using a common comparator] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-13-005. 2013 Authors' conclusions In this research, an indirect comparison methodology used in the context of Health Technology Assessment (HTA). As an example of HTA using indirect comparison, the efficacy of Atomoxetine and Methylphenidate in Adults Attention Deficit Hyperactivity Disorder(ADHD): A Rapid Review conducted by full term for NECA in 2012 was selected as an exemplar. Indirect (...) [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator] [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator] [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult

2013 Health Technology Assessment (HTA) Database.

112. Cogmed Working Memory Training for youth with ADHD: a closer examination of efficacy utilizing evidence-based criteria Full Text available with Trip Pro

be effective for children and adolescents with attention deficit hyperactivity disorder (ADHD). Despite some review limitations, the authors’ conclusions and recommendations for research seem appropriate and are likely to be reliable. Authors' objectives To determine the short and long-term effectiveness of Cogmed Working Memory Training (CWMT) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Searching PsycINFO, PubMed, and the CWMT website were searched for peer-reviewed (...) A, Feirsen N, Bedard AC, Marks D, Uderman JZ, Chimiklis A. Cogmed Working Memory Training for youth with ADHD: a closer examination of efficacy utilizing evidence-based criteria. Journal of Clinical Child and Adolescent Psychology 2013; 42(6): 769-783 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Attention Deficit Disorder with Hyperactivity /physiopathology /therapy; Child; Cognitive Therapy; Evidence-Based Medicine; Humans; Memory, Short-Term /physiology; Randomized

2013 DARE.

113. Clinical and functional outcomes worse in adults diagnosed with ADHD as children

Question: What is effect of childhood attention-deficit/hyperactivity disorder (ADHD) on adult clinical and functional outcomes? Population: Probands: 207 boys (mean age 8 years; range 6–12 years) referred to the medical centre by teachers due to behavioural problems. Only children with hyperactive/impulsive disorder were included; children with aggressive or antisocial behaviour were excluded. Comparators: When probands were aged 18 years (average), men also aged 18 who had attended the medical centre (...) for non-psychiatric reasons between the ages of 6 and 12 were identified. In total, 178 met the inclusion criteria of no symptoms due to behaviour from primary school teachers (parent report). Setting: Medical centre, New York; proband recruitment 1970–1978. Prognostic factors: Diagnosis of ADHD in childhood. Clinical notes were examined and a subsequent confirmatory diagnosis of ADHD was made by comparing with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria

2013 Evidence-Based Mental Health

114. ADHD symptom severity and diagnosis remains relatively stable over 6-year period following diagnosis in preschool

and diagnosis remains relatively stable over 6-year period following diagnosis in preschool Statistics from Altmetric.com Question Question: What is the trajectory of symptom severity and diagnosis of attention-deficit hyperactivity disorder (ADHD) among children of 6 years after diagnosis during preschool? Population: A total of 207 children (75% male) diagnosed with moderate-to-severe ADHD at ages 3–5 years identified from the original Preschool ADHD Treatment Study (PATS). Mean age was 4.4 years (...) ADHD symptom severity and diagnosis remains relatively stable over 6-year period following diagnosis in preschool ADHD symptom severity and diagnosis remains relatively stable over 6-year period following diagnosis in preschool | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2013 Evidence-Based Mental Health

115. Artificial food colour exclusion and free fatty acid supplementation may reduce symptom severity in children with ADHD

Artificial food colour exclusion and free fatty acid supplementation may reduce symptom severity in children with ADHD Statistics from Altmetric.com Question Question: Are dietary and pharmacological interventions effective for the treatment of attention deficit hyperactivity disorder (ADHD)? Outcomes: Post-treatment change from baseline in total ADHD symptom severity as measured by ADHD-specific symptom scales (eg, the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) ADHD (...) Artificial food colour exclusion and free fatty acid supplementation may reduce symptom severity in children with ADHD Artificial food colour exclusion and free fatty acid supplementation may reduce symptom severity in children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2013 Evidence-Based Mental Health

116. The Family-School Success intervention improves some family and educational outcomes in children with attention deficit hyperactivity disorder more than a control psychosocial intervention

for children with attention deficit hyperactivity disorder (ADHD) and their families effective in improving family and educational functioning? Patients: 199 school children in grades 2–6 with DSM-IV ADHD and their families. Setting: One paediatric hospital's ADHD centre, USA. Intervention: The FSS intervention versus the Coping with ADHD through Relationships and Education (CARE) intervention over 12 weeks. The weekly FSS sessions consisted of: six parent group meetings and simultaneous child group (...) The Family-School Success intervention improves some family and educational outcomes in children with attention deficit hyperactivity disorder more than a control psychosocial intervention The Family-School Success intervention improves some family and educational outcomes in children with attention deficit hyperactivity disorder more than a control psychosocial intervention | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you

2013 Evidence-Based Mental Health

117. Review: little evidence that PUFA supplementation improves symptoms in ADHD

effective are polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents? Outcomes: Primary outcome: change in ADHD symptoms using validated scales. Secondary outcomes: behavioural problems, anxiety symptoms, depressive symptoms, quality of life, adverse effects, cost and loss to follow-up. Methods Design: Systematic review and meta-analysis. Data sources: CENTRAL (The Cochrane Library 2011, Issue 2), MEDLINE (1948 to July Week 3, 2011), EMBASE (...) Review: little evidence that PUFA supplementation improves symptoms in ADHD Review: little evidence that PUFA supplementation improves symptoms in ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts

2013 Evidence-Based Mental Health

118. Boys with ADHD are at increased risk of psychosocial, educational and functional impairment in adulthood

with ADHD are at increased risk of psychosocial, educational and functional impairment in adulthood Statistics from Altmetric.com Question Question: What is the burden of psychosocial and functional impairments in adulthood which are associated with attention deficit/hyperactivity disorder (ADHD) in youth? Population: 260 Caucasian boys of ages 6–17 years (140 with DSM-III-R clinician-ascertained ADHD, and 120 without the condition). Those with psychosis, autism, inadequate command of the English (...) language or an IQ of less than 80 were excluded. From this original sample, 79 (56%) of those with ADHD and 90 (75%) of those without the condition took part in a 16 year follow-up. Setting: USA; 1988–2006. Prognostic factors: ADHD during youth. Outcomes: Mood and anxiety disorders (major depressive disorder, bipolar disorder, anxiety disorders, agoraphobia, social phobia, obsessive-compulsive disorder, specific phobia, panic disorder and generalised anxiety disorder); antisocial and substance

2013 Evidence-Based Mental Health

119. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

and intellectual disability Statistics from Altmetric.com Question Question: Are stimulants safe and effective for the treatment of children with attention deficit hyperactivity disorder (ADHD) and intellectual disability? Patients: 122 children and adolescents (aged 7 years; 85% male) with ADHD (International Classification of Disease-10 diagnosis of hyperkinetic disorder) and intellectual disability (IQ 30–69). Recruitment was through clinical referrals and community screening (using the Special Education (...) Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts

2013 Evidence-Based Mental Health

120. Exposure to intimate partner violence and parental depression increases risk of ADHD in preschool children Full Text available with Trip Pro

Exposure to intimate partner violence and parental depression increases risk of ADHD in preschool children Exposure to intimate partner violence and parental depression increases risk of ADHD in preschool children | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Exposure to intimate partner violence and parental depression increases risk of ADHD in preschool children Article Text Children & Adolescents Exposure to intimate partner violence

2013 Evidence-Based Mental Health